Advertisement
β-blocker use is not associated with reduced mortality after acute myocardial infarction without heart failure or left ventricular systolic dysfunction

β-Blocker Use Not Linked to Reduced Mortality After AMI

0
No significant difference in mortality for MI patients without HF, LVSD with, without β-blocker use
For patients with a first demyelinating event (clinically isolated syndrome)

Risk of Conversion to Multiple Sclerosis Down With Minocycline

0
Treatment with minocycline reduces conversion to MS over six months after first demyelinating event
More Americans with HIV are adhering to antiretroviral therapy regimens

Antiretroviral Regimen Adherence Up for Americans With HIV

0
But too many still stop taking drugs a few years after diagnosis
A pill containing the antiviral drugs sofosbuvir

Three-Drug Combo Pill Nearly 100 Percent Effective in Curing Hep C

0
Pill (sofosbuvir, velpatasvir, voxilaprevir) is for patients who have failed with direct-acting antivirals
An appointment-based model which synchronizes medication refills to improve medication adherence is associated with improvement in medication-taking behavior

Medication Adherence Up With Refill Synchronization Model

0
Improvement in medication-taking behavior; cost savings over one year for HTN, DM, hyperlipidemia
Excess weight is associated with increased costs across health care settings

Excess Weight Increases Costs Across Health Care Settings

0
Percentage increases in costs associated with obesity were highest for medications, higher for women
Multidrug-resistant gram-negative bacteria

Drug-Resistant Bacteria Seen in Many Nursing Home Residents

0
More infection-prevention education and policies are needed, researcher says
Gender minority adults have a higher rate of health issues than their cisgender peers

Gender Minority Adults More Likely to Report Poor Health

0
Public health professionals need to pay attention to this vulnerable population, researchers say
Restarting anticoagulation therapy may be cost-effective for patients with a predicted one-year venous thromboembolism risk of 17.5 percent or higher

Restarting Anticoagulation in Certain VTE Cases Cost-Effective

0
Treating patients with predicted VTE risk of 17.5 percent or more may be cost-effective
In a case report published online May 23 in the Annals of Internal Medicine

Severe Cutaneous Adverse Effect From Tocilizumab Described

0
Diffuse, persistent, pruritic maculopapular rash developed 10 days after tocilizumab treatment